|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
22.37 USD |
+3.95% | +8.38% | -22.00% | |
April 26, 2025 at 04:12 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec |
Apr. 26 |
RE |
|
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target |
Apr. 16 |
MT |
|
CG Oncology Files Mixed Shelf |
Mar. 31 |
MT |
|
CG Oncology Inc Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing |
Mar. 28 |
RE |
|
CG Oncology Reports 2024 Year End Financial Results And Provides Business Updates |
Mar. 28 |
RE |
|
CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 28 |
CI |
|
CG Oncology Shares Rise After Reporting Bladder Cancer Drug Durability in Phase 3 Trial |
Mar. 24 |
MT |
|
Cg Oncology, Inc. Announces Complete Response (Cr) At Any Time in A Phase 3 Study |
Mar. 24 |
CI |
|
Certain Options of CG Oncology, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025. |
Mar. 12 |
CI |
|
Certain Common Stock of CG Oncology, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025. |
Mar. 12 |
CI |
|
CG Oncology, Inc. Presents at TD Cowen 45th Annual Healthcare Conference, Mar-05-2025 11:10 AM |
Mar. 05 |
|
|
TD Cowen Initiates CG Oncology at Buy |
Jan. 07 |
MT |
|
CG Oncology, Inc.(NasdaqGS:CGON) added to NASDAQ Biotechnology Index |
Dec. 22 |
CI |
|
CG Oncology Insider Sold Shares Worth $19,600,000, According to a Recent SEC Filing |
Dec. 18 |
MT |
|
CG Oncology Closes $238 Million Offering |
Dec. 16 |
MT |
|
CG Oncology Prices $204.4 Million Public Offering |
Dec. 13 |
MT |
|
CG Oncology Files for Proposed Public Share Offering |
Dec. 11 |
MT |
|
CG Oncology Reports 74.5% Complete Response in Study of Bladder Cancer Candidate |
Dec. 05 |
MT |
|
CG Oncology, Inc. – Special Call |
Dec. 05 |
|
|
CG Oncology, Inc. Announces Topline Data from the Phase 3 Bond-003 Trial in Patients with High-Risk Non-Muscle Invasive Bladder Cancer |
Dec. 05 |
CI |
|
CG Oncology, Inc. to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology 25th Annual Meeting |
Nov. 20 |
CI |
|
CG Oncology’s Q3 Loss Narrows |
Nov. 12 |
MT |
|
CG Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 12 |
CI |
|
CG Oncology, Inc. Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer |
Nov. 11 |
CI |
|
UBS Initiates CG Oncology With Buy Rating, $60 Price Target |
24-10-24 |
MT |
CGON: Dynamic Chart
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
More about the company
Buy
Average target price
62.38USD
Spread / Average Target
+178.83%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
